The U.S. Food and Drug Administration has approved Isentress (raltegravir) for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2 to 18. Read more.
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.